AMLX
Price
$38.66
Change
-$1.00 (-2.52%)
Updated
Aug 21 closing price
Capitalization
4.31B
74 days until earnings call
Intraday BUY SELL Signals
IRON
Price
$79.81
Change
+$0.97 (+1.23%)
Updated
Aug 21 closing price
Capitalization
3.06B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs IRON

AMLX vs IRON Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMLX vs. IRON commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and IRON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (AMLX: $38.66 vs. IRON: $79.81)
Brand notoriety: AMLX and IRON are both not notable
AMLX represents the Pharmaceuticals: Generic, while IRON is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 136% vs. IRON: 53%
Market capitalization -- AMLX: $4.31B vs. IRON: $3.06B
AMLX [@Pharmaceuticals: Generic] is valued at $4.31B. IRON’s [@Biotechnology] market capitalization is $3.06B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileIRON’s FA Score has 0 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • IRON’s FA Score: 0 green, 5 red.
According to our system of comparison, both AMLX and IRON are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 4 TA indicator(s) are bullish while IRON’s TA Score has 3 bullish TA indicator(s).

  • AMLX’s TA Score: 4 bullish, 4 bearish.
  • IRON’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, AMLX is a better buy in the short-term than IRON.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а +78.73% price change this week, while IRON (@Biotechnology) price change was +1.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.60%. For the same industry, the average monthly price growth was +6.53%, and the average quarterly price growth was +30.86%.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

AMLX is expected to report earnings on Nov 05, 2026.

IRON is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($4.31B) has a higher market cap than IRON($3.06B). AMLX YTD gains are higher at: 220.033 vs. IRON (0.504). AMLX has higher annual earnings (EBITDA): -158.8M vs. IRON (-241.67M). IRON has more cash in the bank: 718M vs. AMLX (280M). AMLX has less debt than IRON: AMLX (5.63M) vs IRON (60.9M). AMLX (0) and IRON (0) have equivalent revenues.
AMLXIRONAMLX / IRON
Capitalization4.31B3.06B141%
EBITDA-158.8M-241.67M66%
Gain YTD220.0330.50443,683%
P/E Ratio2.69N/A-
Revenue00-
Total Cash280M718M39%
Total Debt5.63M60.9M9%
FUNDAMENTALS RATINGS
IRON: Fundamental Ratings
IRON
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
61
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
22

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXIRON
RSI
ODDS (%)
Bearish Trend 3 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
72%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 10 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
71%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
IRON
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MPG6.170.94
+18.04%
Leverage Shares 2X Long MP Daily ETF
LABU317.2012.29
+4.03%
Direxion Daily S&P Biotech Bull 3X ETF
IOO143.800.54
+0.38%
iShares Global 100 ETF
CZA126.29N/A
N/A
Invesco Zacks Mid-Cap ETF
MSTI20.17-0.03
-0.12%
Madison Short-Term Strategic Income ETF

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
-2.52%
OCUL - AMLX
46%
Loosely correlated
-0.09%
LRMR - AMLX
45%
Loosely correlated
+0.48%
JAZZ - AMLX
43%
Loosely correlated
+2.24%
RGNX - AMLX
43%
Loosely correlated
-3.07%
IDYA - AMLX
43%
Loosely correlated
+1.43%
More

IRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, IRON has been loosely correlated with NCEL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IRON jumps, then NCEL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRON
1D Price
Change %
IRON100%
+1.23%
NCEL - IRON
54%
Loosely correlated
-2.04%
AMLX - IRON
39%
Loosely correlated
-2.52%
REPL - IRON
38%
Loosely correlated
+5.12%
MLTX - IRON
38%
Loosely correlated
-0.69%
UPB - IRON
36%
Loosely correlated
+1.75%
More